GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Cyclically Adjusted Revenue per Share

Sage Therapeutics (FRA:SG7) Cyclically Adjusted Revenue per Share : €4.51 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sage Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was €0.121. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.51 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Sage Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-05), Sage Therapeutics's current stock price is €10.175. Sage Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €4.51. Sage Therapeutics's Cyclically Adjusted PS Ratio of today is 2.26.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Sage Therapeutics was 10.97. The lowest was 2.26. And the median was 5.86.


Sage Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sage Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Cyclically Adjusted Revenue per Share Chart

Sage Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 5.27 4.60

Sage Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.98 4.75 4.73 4.60 4.51

Competitive Comparison of Sage Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Sage Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sage Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sage Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.121/131.7762*131.7762
=0.121

Current CPI (Mar. 2024) = 131.7762.

Sage Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 1.655 106.317 2.051
201809 0.000 106.507 0.000
201812 0.005 105.998 0.006
201903 0.008 107.251 0.010
201906 0.015 108.070 0.018
201909 0.063 108.329 0.077
201912 0.034 108.420 0.041
202003 0.040 108.902 0.048
202006 0.019 108.767 0.023
202009 0.027 109.815 0.032
202012 16.224 109.897 19.454
202103 0.023 111.754 0.027
202106 0.023 114.631 0.026
202109 0.021 115.734 0.024
202112 0.025 117.630 0.028
202203 0.024 121.301 0.026
202206 0.024 125.017 0.025
202209 0.030 125.227 0.032
202212 0.045 125.222 0.047
202303 0.052 127.348 0.054
202306 0.038 128.729 0.039
202309 0.042 129.860 0.043
202312 1.192 129.419 1.214
202403 0.121 131.776 0.121

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sage Therapeutics  (FRA:SG7) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sage Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.175/4.51
=2.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Sage Therapeutics was 10.97. The lowest was 2.26. And the median was 5.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sage Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics (FRA:SG7) Business Description

Industry
Traded in Other Exchanges
Address
215 First Street, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines